CUPR

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

Acquiring 100% of East Coast Podiatry (five clinics) and Orchard Clinic (two clinics) for approximately S$4.0 million (approximately US$3.1 million)Target Group generated FY2025 unaudited revenue of approximately S$9.1 million and unaudited normalized EBITDA of approximately S$1.2 million, based on unaudited management accountsSellers’ consideration shares subject to a lock-upAdds an established clinical platform directly aligned with Cuprina’s wound-care and collagen technologies SINGAPORE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or the "Company"), a biomedical company developing and marketing products for the chronic wounds, infertili

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it closed the sale of an additional 648,373 Class A ordinary shares of the Company, pursuant to the full exercise of the underwriter’s over-allotment option granted in connection with the Company’s public offering ("PO", together with such over-allotment closing, the "Offering"), at a public offering price of $1.15 per share, for a total of approximately $745,629 of gross proceeds to the Company, before d

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced the closing of its previously announced public offering of an aggregate 4,322,489 Class A Ordinary Shares ("the Offering") at a price of $1.15 per share ("the Offering Price") to the public, for a total of approximately $4.97 million of gross proceeds to the Company, before deducting underwriting discounts and offering expenses. The Company has granted the underwriter a 45-day option to purchase up to an addi

424B4 - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced the pricing of its firm commitment public offering of an aggregate 4,322,489 shares of its Class A Ordinary Shares ("the Offering"), all of which are being offered by CUPR at a public offering price of $1.15 per share ("the Offering Price"), for a total of approximately $4.97 million of gross proceeds to the Company, before deducting underwriting discounts and offering expenses. The Company has granted the un

EFFECT - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

F-1/A - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SCHEDULE 13G - Cuprina Holdings (Cayman) LTD (0001995704) (Subject)

F-1 - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

20-F/A - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, June 15, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("CUPR" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that an indirectly wholly-owned subsidiary of the Company, Cuprina Pte. Ltd. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MEDIFLY Maggots™, its medical-grade Lucilia cuprina larvae used in maggot debridement therapy (MDT). To the Company's knowledge, MEDIFLY Maggots™ is the first maggot debridement product to receive U.S. FDA 510(k) clearance using the Lucilia cuprina species.

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, June 12, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that on June 11, 2026 it has regained compliance with the Nasdaq Capital Markets Listing Requirements. As previously disclosed on May 29, 2026, the Company received a Staff Delisting Determinations Letter (the "Staff Determination") indicating that the Company's securities had closed below $1.00 per share for 30 consecutive business days, failing to meet the minimum bid price requirement under Listing Rule 555

SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it completed a reverse stock split on May 27, 2026, and requested  a hearing before the Nasdaq Hearings Panel (the "Panel"), in response to a staff determination letter (the "Letter") received on May 27, 2026, from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq"). The Letter notified the Company that, due to the Company's failure to regain compliance with a minim

SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it plans to implement a 1-for-8 share consolidation of its Class A ordinary shares ("Class A Ordinary Shares") and Class B ordinary shares ("Class B Ordinary Shares") (the "Share Consolidation"), effective on or around May 27, 2026. Beginning with the opening of trading on or around May 27, 2026, the Company's Class A Ordinary Shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capi

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

6-K/A - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

20-F - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)